Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|A091105||Alliance||A Phase III; Double Blind; Randomized; Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)||Adult CIRB - Late Phase Emphasis||Available to Open|
|NCICOVID||NCI||NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study||Adult CIRB - Late Phase Emphasis||Available to Open|
|S2000||SWOG||A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases||Adult CIRB - Late Phase Emphasis||Available to Open|
|S0307||SWOG||Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|NSABP-B-38||NSABP||A Phase III; Adjuvant Trial Comparing Three Chemotherapy Regimens in Women with Node-Positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-Dense (DD) Doxorubicin/Cyclophosphamide Followed by DD Paclitaxel (DD AC->P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC->PG)||Adult CIRB - Late Phase Emphasis||Completed|
|E1305||ECOG||A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|
|ACOSOG-Z4099||ACSOG||A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) versus Stereotactic Body Radiation Therapy in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)<br><br>||Adult CIRB - Late Phase Emphasis||Completed|
|S1900C||SWOG||A Phase II Study of Talazoparib plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LungMAP Sub-Study)||Adult CIRB - Late Phase Emphasis||Available to Open|
|E5204||ECOG||Intergroup Randomized Phase III Study of Postoperative Oxaliplatin; 5-Fluorouracil; and Leucovorin vs Oxaliplatin; 5-Fluorouracil; Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation||Adult CIRB - Late Phase Emphasis||Completed|
|RTOG-0617||RTOG||A Randomized Phase III Comparison of Standard-Dose (60 Gy) versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung Cancer||Adult CIRB - Late Phase Emphasis||Available to Open|